



Biotech Daily

Thursday September 3, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ACTINOGEN UP 12%; COMPUMEDICS DOWN 16%**
- * **WEHI FEDERAL \$18.8m FOR BRAIN CANCER DRUGS**
- * **SYDNEY UNI 'NANO-BONE 80% MORE BONE GROWTH, IN RATS'**
- * **ASX WAIVES ALCIDION APPENDIX 4Cs**
- * **GENETIC SIGNATURES RECEIVES BCAL 249D NOTICE**
- * **EMVISION \$337k REGIONAL TRIAL MILESTONE**
- * **IMRICOR: FDA ACCEPTS 7 PRODUCTS MANUFACTURING FILINGS**
- * **MEMPHASYS TÜRKIYE FELIX APPROVAL; 1st SALE**
- * **CLEO BEGINS OVARIAN CANCER TEST VALIDATION**
- * **RENERVE 5.5m BOARD OPTIONS AGM**
- * **RETAIL EMPLOYEES SUPER BELOW 5% OF PYC**
- * **PAINCHEK LOSES DIRECTOR ROSS HARRICKS**

MARKET REPORT

The Australian stock market was up 0.46 percent on Thursday September 3, 2026, with the ASX200 up 41.7 points to 9,020.1 points. Eighteen of the Biotech Daily Top 40 companies were up, 13 fell, seven traded unchanged and two were untraded.

Actinogen was the best, up 0.5 cents or 11.6 percent to 4.8 cents, with 22.5 million shares traded. Paradigm climbed 9.1 percent; Avita was up 7.5 percent; Cyclopharm and Imricor improved more than four percent; Cochlear, Neuren, Nova Eye and Telix were up more than three percent; Medical Developments, Nanosonics, Polynovo and Starpharma rose two percent or more; 4D Medical, CSL, Emvision and Proteomics were up one percent or more; with Alcidion, Mesoblast, Orthocell and Pro Medicus up by less than one percent.

Compumedics led the falls, down 4.5 cents or 16.4 percent to 23 cents, with 20,682 shares traded. Optiscan lost 9.4 percent; Atomo and Micro-X were down more than five percent; Immutep fell 4.1 percent; Artrya, Lumos, Racura and Resonance were down three percent or more; Imugene and Saluda shed more than two percent; Clinuvel and Prescient were down more than one percent; with Resmed down by 0.6 percent.

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says it has \$18.8 million Federal Government grant to develop brain-penetrating brain cancer treatments.

WEHI said it would use “a pioneering approach” to develop a class of cancer drugs that can break the blood-brain barrier, that blocks most drugs from entering the brain.

The Institute said the Medical Research Future Fund grant would fund the work with the Brain Cancer Centre, the Royal Melbourne Hospital, the Peter MacCallum Cancer Centre, the Monash Institute of Pharmaceutical Sciences, the University of Queensland and the University of Technology Sydney.

WEHI said the blood-brain barrier prevented toxins and infections from passing into the brain but was “so fiercely protective, it also blocks around 98 percent of cancer drugs”.

The Institute said the brain needed “a steady supply of essential nutrients, like iron and glucose, to support its healthy growth and development [and] uses a range of natural delivery systems that transport them from the bloodstream into the brain”.

WEHI said cells in the blood-brain barrier contained specialized ‘docking stations’ that recognized the nutrient-carrying proteins and drew them into the brain”.

The Institute said it would develop nanobody-drug conjugates, or antibody fragments, that could deliver drugs more precisely while minimizing harm to healthy tissue.

WEHI said nanobodies that “bind to the transferrin receptor will then be designed, providing a unique way to ferry drugs into the blood-brain barrier by leveraging the iron transport system”.

The Institute said it was the “first time a research group will use this approach”.

The Federal Minister for Health and Ageing Mark Butler said the project consolidated “Australia’s proud record of world-leading medical research”.

“Bold and innovative research like this is needed to spearhead better treatments for brain cancer,” Mr Butler said.

THE UNIVERSITY OF SYDNEY

The University of Sydney says a rat study shows its biodegradable ‘nano-bone’ led to about “80 percent more new bone than a material control after eight weeks”.

The University of Sydney said rather than delivering manufactured growth factors, its calcium-aluminosilicate nano-material activated a naturally occurring growth factor called latent transforming growth factor beta 1 (TGF- β 1) which existed in the body.

The University said once activated the material attracted “bone-forming stem cells to the injury site and encourages them to develop into bone-producing cells... [and] over time, this process replaces the material with the body’s own tissue”.

The University said the ‘nano-bone’ activated a bone-repair growth factor with about 10 times the level achieved using conventional methods and promoted blood clotting within around 30 seconds, helping stabilize the injury site during the earliest stages of healing”.

The study, titled ‘Multifunctional Mesoporous Calcium-aluminosilicate Nanoparticles Enable Heterogeneous Activation of Endogenous Transforming Growth Factor 1 and Rapid Hemostasis for Bone Repair’ was published in the journal American Chemical Society (ACS) Nano, but no link was available at the time of publication.

The University said the study was “the first to demonstrate a single nano-material platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration”.

The University of Sydney said while the technology was pre-clinical, researchers believed it could have applications beyond cleft lip and palate, including traumatic injuries, tooth loss and other difficult to repair bone defects”.

GENETIC SIGNATURES, BCAL DIAGNOSTICS

Genetic Signatures says Bcal wants to replace chair Mike Aicher with former Genetic Signatures chief executive officer John Melki and Susan Forrester as directors.

Genetic Signatures said that it had received a section 249D notice from Bcal.

Last month, Bcal said it became a substantial shareholder in Genetic Signatures with 23,173,644 shares, or 10.2 percent of the company (BD: Jul 3, 2026).

The previous day, Genetic Signatures said it was not notified in advance of Bcal's announcement and had no prior knowledge of the share acquisition (BD: Jul 2, 2026).

Last week, Bcal said it had increased its holding to 41,923,644 shares (18.46%).

At that time, in a separate announcement, Genetic Signatures said it was in discussions with Microba Life Sciences to assess a potential merger (BD: Aug 26, 2026).

Today, Genetic Signatures said it had undertaken a review of its share register and noted that there was "no recorded increase in Bcal's shareholding in the company".

The company said its share register indicated "that the same number of shares purportedly acquired by Bcal were held by an entity named Lawn Views Pty Ltd, with sole director Angela Williams, whose spouse is David Williams, the former chair of Medical Developments, Polynovo and Inoviq and the current chair of Arovella.

Genetic Signatures said Lawn Views' address was Level 29, 55 Collins Street, the registered office of Kidder Williams Ltd.

The company said based on its review of the ASIC companies' register, the company understands that Lawn Views' "sole director and shareholder is Angela Kate Williams".

Genetic Signatures said it wrote to Bcal asking if it owned the 18,750,000 shares bought on August 26, if any of its associates own shares in Genetic Signatures and whether any relevant agreement exists between Bcal and Lawn Views or any of its associates.

The company said it had received a request from Bcal pursuant to section 249D of the Corporations Act (2001) for the directors of Genetic Signatures to call and arrange a general meeting of shareholders for the purposes of considering the removal of chair Mr Aicher and the appointment of Mr Melki and Ms Forrester as directors.

Genetic Signatures said it was "considering the section 249D notice and, if it considers the notice to be valid ... will comply with its relevant obligations under the Corporations Act (2001) and will undertake the necessary steps to convene a general meeting".

Separately, Bcal said that the vendor of the 18,750,000 shares acquired on August 26, 2026 remained the registered holder of the shares "as is always the case, pending registration of the transfer by the share registry of Genetic Signatures".

The company said the transfer of the second parcel of shares was registered yesterday and that Genetic Signatures "appears to have reviewed an outdated version of its share register from August 31, 2026".

Bcal said it had engaged corporate adviser and investment bank Kidder Williams to assist it with the acquisition of its interest in Genetic Signatures and that it understood Kidder Williams "used an associated entity to facilitate the acquisition in the proper performance of the functions attaching to its professional capacity in performing that mandate".

The company said Kidder Williams was "not an associate of Bcal".

Bcal was up 0.1 cents or 1.5 percent to 6.9 cents.

Genetic Signatures fell 0.3 cents or 3.3 percent to 8.7 cents.

ALCIDION GROUP

Alcidion says the ASX has removed the requirement for the company to lodge Appendix 4C quarterly cash flow reports, reflecting its "strengthened financial position".

Alcidion was up 0.05 cents or 0.5 percent to 9.75 cents.

EMVISION MEDICAL DEVICES

Emvision says it has received another \$337,425 progress payment from the Federal Government after completing site visits for its regional 'Emu' brain scanner study. Last year, Emvision said it had \$3 million from the Federal Government's Cooperative Research Centres Projects (CRC-P) program to conduct studies of its portable 'Emu' brain scanner for improving stroke care in regional Australia (BD: Aug 15, 2025). Today, the company said the study targeted regional and remote hospitals without timely computed tomography (CT) access where suspected stroke patients must typically be transferred by road or air before diagnosis was possible. Emvision said site visits in regional South Australia were complete, with protocol and ethics preparation "well advanced". The company said next steps included protocol finalization, ethics approval, site contracting and research governance approvals, with the inclusion of additional sites also being considered and it would provide further updates as milestones were met. Emvision was up 2.5 cents or 1.4 percent to \$1.78.

IMRICOR MEDICAL SYSTEMS

Imricor says the US Food and Drug Administration has evaluated and accepted the manufacturing modules for pre-market approval submissions for seven products. Imricor said the manufacturing module covered the design, manufacturing and quality processes for six of its products undergoing FDA pre-market approval including the Vision-magnetic resonance (MR) ablation catheter and the RF-5000 ablation generator and pump, as well as an undisclosed third-party product that it would distribute. Earlier this year, the company said it had FDA 510(k) clearance for its Vision-MR catheter and Northstar mapping and guidance system; and later, filed for clearance for its Navtrac and Navtrac-MR steerable cardiac catheter introducers (BD: Jan 18, 29, Jul 20, 2026). Today, Imricor said the module included "design controls, the receipt, inspection and storage of raw materials, build procedures, process validation, part and device traceability, and the applicable quality management systems". The company said that the module was "not expected to be re-reviewed as part of the final [pre-market approval] review unless changes are subsequently made to its contents". Imricor said with the manufacturing module closed it had "another major milestone toward FDA approval of the products engaged in the [pre-market approval] process". Imricor was up 8.5 cents or 4.6 percent to \$1.92.

MEMPHASYS

Memphasys says it has product registration in Türkiye for its Felix sperm separation system, with the first commercial sale to its distribution partner complete. Last year, Memphasys said it had a \$325,000, five-year deal with International Technical Legacy (ITL) to supply Felix to 15 countries in the Middle East and North Africa, on receiving Conformité Européenne (CE) mark approval (BD: Sep 8, 2025). Today, the company said Türkiye was added to the ITL distribution territory following CE Mark approval, with the first commercial sale in Türkiye completed, comprising 100 Felix cartridges and two consoles, but did not disclose the commercial terms of the sale. The company said the first order provided a platform from which the local distributor could undertake demonstrations, education and customer conversion activities and it expected additional orders as in-vitro fertilization (IVF) clinics were engaged by partners. Memphasys was up 0.1 cents or 20 percent to 0.6 cents with 27.1 million shares traded.

CLEO DIAGNOSTICS

Cleo says it will begin analytical validation of its pre-surgical ovarian cancer test following receipt of the first production batch of commercial test kits.

In March, Cleo said it had achieved the target 514 blood samples collected for its pivotal US trial of its pre-surgical ovarian cancer test (BD: Mar 31, 2026)

In July, the company said it had completed the development and preparation activities required for analytical validation of its ovarian cancer blood tests (BD: Jul 13, 2026).

Today, Cleo said manufacturing and delivery of the first batch followed completion of assay development and optimization activities required to translate its technology into a commercial test format and was "a significant milestone in the company's regulatory program".

The company said it had received 125 test kits as part of the first batch which would undergo standard internal quality control and documentation procedures prior to formal commencement of analytical validation.

Cleo said it expected the quality control process to take one-to-two weeks.

The company said analytical validation was designed to show the assay performed "reliably and reproducibly from an analytical perspective" and was a critical component of the regulatory evidence required for a US Food and Drug Administration 510(k) submission, expected by July 2027.

Cleo was up five cents or 14.3 percent to 40 cents.

RENERVE

Renerve says its annual general meeting will vote to issue 5,500,000 options to chair Maja McGuire, managing-director Dr Julian Chick and director Dr Paul Savage.

Renerve said investors would vote to issue Ms McGuire 1,500,000 options, Dr Chick 3,000,000 options and Dr Savage 1,000,000 options, in three equal tranches, with each tranche exercisable at 15 cents, 20 cents and 25 cents, respectively within four years from the grant date.

The company said shareholders would vote to adopt the remuneration report, elect Ms McGuire and Dr Savage as directors, ratify the prior issue of shares to scientific advisory board members in lieu of cash fees, ratify the prior issue of shares to Spark Plus and convertible notes to Riverfort Global Opportunities as well as approve the additional 10 percent placement capacity.

The meeting will be held at Cornwalls, Level 4, 380 Collins Street, Melbourne on October 5, 2026 at 2pm (AEDT).

Renerve was untraded at 7.7 cents.

PYC THERAPEUTICS

Retail Employees Superannuation Pty Ltd says that it has ceased its substantial shareholding in PYC.

Sydney's Retail Employees Superannuation said that between June 15 and August 31, 2026 it bought and sold shares, with the single largest sale 2,339,154 shares for \$5,348,998, or \$2.29 a share.

PYC was up 14 cents or 5.8 percent to \$2.57 with 4.6 million shares traded.

PAINCHEK

Painchek says Ross Harricks notified the company of his resignation as a non-executive director, effective from yesterday.

Painchek said Mr Harricks had been a director since September 30, 2016 and thanked him for his contribution and service to the company.

Painchek was up 0.9 cents or 9.4 percent to 10.5 cents.